Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.58 |
| ▸ | WNT3A | P56704 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200312 | 0.86 | LMNA (0.61) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL2216212 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL11542756 | 0.84 | HDAC1 (0.79) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL2516127 | 0.81 | LMNA (0.75) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL170394 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL18755474 | 0.80 | ALDH1A1 (0.81) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL992300 | 0.79 | ALDH1A1 (0.67) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL20620075 | 0.79 | ALDH1A1 (0.76) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL10352206 | 0.78 | ALDH1A1 (0.77) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL759462 | 0.78 | ALDH1A1 (0.84) | ALDH1A1LMNAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ALDH1A1 2806/4885LMNA 4293/4885POLB 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.